Table 2.
Laboratory data at presentation and initial treatment in children with infantile-onset inflammatory bowel disease.
| Parameter | Value |
|---|---|
| Laboratory | |
| White blood cells (x 103), mean ± SD | 15.3 ± 6.4 |
| Hemoglobin (gr/dl), mean ± SD | 9.6 ± 1.4 |
| MCV (fl), mean ± SD | 70.3 ± 8.3 |
| Platelet count (x 103), mean ± SD | 583 ± 165 |
| Albumin (gr/dl), mean ± SD | 3.3 ± 0.8 |
| CRP (mg/L), median (IQR) | 19 (4–83) |
| ESR (millimeter/hour), median (IQR) | 29 (20–55) |
| Serology | |
| ASCA positive, n (%) | 1/12 (8) |
| ANCA positive, n (%) | 2/11 (18) |
| Genetic evaluation a | |
| IL-10 Receptor mutation, n (%) | 1/10 (10) |
| CARMIL2 mutation, n (%) | 1/10 (10) |
| Medicationsa n (%) | |
| 5-ASA | 17/23 (74) |
| Aza/6-MP | 16/23 (70) |
| Corticosteroids | 20/23 (87) |
| Anti TNF-α | 7/23 (30) |
| TPNb | 8/16 (50) |
| Surgery at first hospitalization, n (%) | 6/23 (26) |
| Ileostomy | 1/23 (4.3) |
| Ileostomy + subtotal colectomy | 1/23 (4.3) |
| Ileostomy + total colectomy | 4/23 (17.4) |
MCV, mean corpuscular volume; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ASCA, anti-saccharomyces cerevisiae antibody; ANCA, antineutrophil cytoplasmic antibody; IL, interleukin; TNF, tumor necrosis factor; Aza, azathioprine; 6-MP, 6-mercaptopurine; 5-ASA, 5-aminosalicylic acid; TPN, total parenteral nutrition.
a
21/23 (91%) of the patients were treated with more than one medication.
b
Data were available for only 16 patients.